Faeth Therapeutics stock maintained at Buy by TD Cowen on trial data

TD Cowen maintained a Buy rating on Faeth Therapeutics (FTH) after its PIKTOR study showed a 33% objective response rate and 7.4 months median progression-free survival, exceeding chemotherapy benchmarks. FTH stock surged 14.7% last week, trading at $22.05. Analysts note potential in endometrial cancer treatment, with mixed views on valuation. Recent ratings include Overweight (Cantor Fitzgerald), Market Outperform (Citizens, $51 target), and Outperform (William Blair, $66 target).

Original reporting
Published Nov 9, 2026, 12:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$FTH
Bullish
high confidence
Mentioned
$FTH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FTHBullishHigh
01

Why it matters

The PIKTOR trial data provide the first substantive efficacy readout, likely influencing short‑term price action and longer‑term valuation.

02

Market read

First disclosure of pivotal trial data for a micro‑cap biotech, driving immediate market reaction and potential sector ripple effects.

03

What to watch

Potential competition from other endometrial cancer agents and the need for Phase III confirmation may limit upside.

Relevance 8/10Novelty 8/10Timing: same-day

Background

Faeth Therapeutics (FTH) is a Nasdaq‑listed biotech focused on oncology, recently expanding its board and receiving multiple analyst coverage upgrades.

Company-level read

Ticker impact

$FTHBullishHigh confidence
Context

TD Cowen reiterated a Buy rating on Faeth Therapeutics after the company released its PIKTOR trial results showing a 33% objective response rate and 7.4 months median progression‑free survival.

Expected impact

likely upward pressure as investors price in the stronger-than‑expected efficacy data.

Evidence & confidence

First‑time disclosure of pivotal trial results for a micro‑cap biotech typically drives significant price moves; the data exceed key comparators despite missing the 40% response target.

Market effects

Positive read on early‑stage oncology pipelines may lift peer biotech stocks in the cancer‑therapy space.

Limited to U.S. biotech investors; no broader regional effect.

Modest, as the data pertain to a niche endometrial cancer indication.

Counterpoint

The response rate fell short of the 40% hoped for, and safety signals (hyperglycemia, stomatitis) could temper enthusiasm.

Key entities

  • TD Cowen

    Reiterated a Buy rating on Faeth Therapeutics based on trial results.

  • Faeth Therapeutics

    Biotech company reporting PIKTOR trial outcomes.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.